Journal Highlight : Liquid Biopsy and Non-Invasive Oncology
The journal welcomes scholarly contributions related to minimally invasive diagnostic and monitoring approaches in cancer research and clinical oncology. This section focuses on research that advances the development and clinical application of liquid biopsy technologies and other non-invasive oncology methods for early cancer detection, disease monitoring, therapeutic guidance, and personalized cancer care.
The journal encourages submissions in areas including Liquid Biopsy Technologies, Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Cell-Free DNA and RNA Analysis, Exosomes and Extracellular Vesicles, Molecular Biomarkers, Cancer Genomics, Non-Invasive Molecular Diagnostics, and Cancer Screening and Early Detection. Research related to Multi-Omics Approaches in Liquid Biopsy, Epigenetic Biomarkers, Proteomic and Metabolomic Profiling, Companion Diagnostics, and AI-Assisted Cancer Diagnostics is also welcomed.
Submissions focusing on Disease Monitoring and Minimal Residual Disease Detection, Treatment Response Assessment, Therapeutic Resistance Monitoring, Precision Oncology, Personalized Cancer Medicine, Biomarker Validation, Translational Oncology, and Clinical Applications of Non-Invasive Diagnostics are encouraged. The journal also welcomes studies investigating the integration of liquid biopsy technologies into routine oncology practice, clinical trials, population screening programs, and longitudinal cancer management.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Clinical and Translational Studies, Diagnostic Evaluation Studies, Technology and Methodology Articles, Case Reports, and Clinical Trial Reports that contribute to advancements in non-invasive oncology and liquid biopsy research.
Through this focus area, the journal aims to support research that improves non-invasive cancer diagnostics, enhances real-time disease monitoring, advances precision oncology strategies, and contributes to innovative and evidence-based cancer care worldwide.
